Moderna already waved their rights last year [0]. But the production of such vaccines is not easy and I believe that an organization grows and learns as a whole as a solution so complex is developed. Consequently it is not easy to replicate what they do. I think at best this puts a cap on the vaccine's price since "in theory" given enough financial incentive the vaccine can be reproduced. That's my theory, feel free to prove me wrong.

Imho: If this becomes real, don't expect big benefits. I appreciate what Moderna did but forcing other companies to do the same may be overkill for little benefit and I wonder what the long term effect is on companies' willingness to focus on a vaccine for the next pandemic. Perhaps companies realize that waiving IP rights is good PR, or they can do it for parts of the process that is easier to scale or outsource to 3rd parties.

What happens to startups that do find an easy to copy vaccine production process and they know their IP will be taken from them? I honestly don't know but I feel that they should be fairly compensated... But what's fair. IP is just so difficult. I wonder what a world without it would look like. More company secrets, that's for sure.

[0] https://investors.modernatx.com/news-releases/news-release-d...